Elevance Health, Inc.
ELV
$395.10
+0.07%
Elevance Health, Inc. is a leading U.S. health insurer providing medical benefits to approximately 45 million members through employer, individual, and government-sponsored plans, operating within the Healthcare Plans industry. The company's distinct competitive identity stems from its position as the largest single provider of Blue Cross Blue Shield branded coverage, holding licenses in 14 states, and its expansion into pharmacy benefit management and healthcare services through strategic acquisitions. The current investor narrative is heavily influenced by regulatory developments affecting government-sponsored programs, particularly the recent larger-than-expected 2027 Medicare Advantage payment increase announced by CMS, which has boosted sector-wide sentiment and revenue visibility for Elevance and its peers.…
ELV
Elevance Health, Inc.
$395.10
Investment Opinion: Should I buy ELV Today?
Rating: Hold. The core thesis is that ELV offers a compelling valuation and regulatory tailwind, but these are counterbalanced by significant near-term earnings volatility that warrants caution.
Supporting Evidence: The stock trades at a reasonable forward PE of 13.28x, near the low end of its historical range. Analyst sentiment is bullish with an implied average target offering ~59% upside. The company generates strong annual free cash flow of $3.17B and maintains a healthy ROE of 12.9%. Furthermore, the recent CMS payment boost for 2027 provides a concrete, multi-year growth catalyst for its government business.
Risks & Conditions: The two biggest risks are 1) the continuation of severe quarterly margin volatility, and 2) revenue growth deceleration below the high-single digits. This Hold rating would upgrade to a Buy if the company demonstrates margin stabilization (net margin consistently above 3%) in the next two quarters, or if the PE multiple compresses further towards 12x on unwarranted selling. It would downgrade to Sell if revenue growth decelerates below 5% YoY or if free cash flow generation meaningfully deteriorates. Relative to its own history and defensive profile, the stock appears fairly valued to slightly undervalued, but not deeply enough to overlook the earnings quality concerns.
Sign up to view all
ELV 12-Month Price Forecast
Elevance Health presents a classic 'wait-and-see' opportunity. The valuation and sector catalyst are compelling, but the severe erosion in quarterly profitability makes the near-term path highly uncertain. The stance is neutral with medium confidence because the positive and negative factors are nearly in equilibrium. The investment thesis hinges entirely on the next two quarterly earnings reports. Evidence of margin stabilization would be a powerful catalyst to upgrade to a bullish stance, as it would validate the bull case and unlock the significant upside to analyst targets. Conversely, another quarter of sub-1.5% net margins would confirm deteriorating fundamentals, necessitating a downgrade to bearish.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Elevance Health, Inc.'s 12-month outlook, with a consensus price target around $513.63 and implied upside of +30.0% versus the current price.
Average Target
$513.63
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$316 - $514
Analyst target range
Analyst coverage for Elevance Health is active, with six analysts providing estimates, and the institutional sentiment is overwhelmingly bullish, as evidenced by recent ratings from major firms like JP Morgan, Barclays, and Wells Fargo all maintaining 'Overweight' or equivalent 'Buy' ratings. The consensus average target price implied by the estimated EPS of $46.51 and the forward PE of 13.28x is approximately $617.70, which would represent a substantial upside of nearly 59% from the current price, though this is a derived figure as a direct average target price was not provided in the data. The target range, inferred from estimated EPS, spans from a low of $598.00 (based on the low EPS estimate of $45.03) to a high of $646.00 (based on the high EPS estimate of $48.65), indicating a spread of about 8%, which reflects moderate uncertainty; the high target likely assumes successful execution on growth initiatives and stable regulatory environment, while the low target may factor in margin pressures or competitive challenges.
Bulls vs Bears: ELV Investment Factors
The investment debate for Elevance Health centers on the tension between compelling valuation/sector tailwinds and significant earnings volatility. The bull case is anchored by a low PE multiple, a positive regulatory catalyst for its Medicare business, strong analyst targets, and a defensive profile. The bear case focuses on the alarming quarterly margin compression and decelerating revenue growth, which undermine earnings quality and predictability. Currently, the bull side holds stronger evidence due to the concrete, forward-looking catalyst from CMS and the stock's valuation discount, but the thesis is highly contingent on stabilizing profitability. The single most important factor is whether Q4's margin weakness was an anomaly or the start of a deteriorating trend; its resolution will dictate the stock's ability to re-rate higher towards analyst targets or languish due to earnings uncertainty.
Bullish
- Strong Sector Catalyst from CMS: The recent larger-than-expected 2027 Medicare Advantage payment increase from CMS has boosted revenue visibility and sentiment across the managed care sector. This regulatory tailwind directly benefits Elevance's significant government-sponsored business, providing a multi-year growth runway.
- Attractive Valuation at 13.7x PE: The stock trades at a trailing PE of 13.73x, near the lower end of its historical range (11.28x to 35x+), suggesting a value-oriented multiple. This valuation appears reasonable for a profitable, large-scale insurer with a 12.9% ROE, potentially pricing in excessive risk.
- Robust Analyst Sentiment & Upside: Analyst consensus is overwhelmingly bullish, with major firms maintaining 'Overweight' ratings. The derived average target price of ~$617.70 implies nearly 59% upside from the current price, based on a forward PE of 13.28x and estimated EPS of $46.51.
- Strong Balance Sheet & Cash Flow: The company maintains a healthy financial position with a debt-to-equity ratio of 0.76, a current ratio of 1.24, and generates robust annual free cash flow of $3.17 billion. This provides ample internal funding for growth, acquisitions, and shareholder returns.
Bearish
- Severe Quarterly Margin Volatility: Profitability is highly inconsistent, with the Q4 2025 net margin compressing to 1.10% from 2.34% in Q3 and 4.47% in Q1 2025. This volatility, alongside a sequential gross margin contraction from 24.79% to 23.48%, raises concerns about earnings predictability and cost management.
- Revenue Growth Deceleration: While Q4 2025 revenue grew 9.47% YoY, this represents a deceleration from the 12.4% growth seen in Q3 2025. This trend, if sustained, could challenge the growth narrative and pressure valuation multiples.
- Recent Technical Pullback from Highs: The stock has declined 3.42% over the past month, underperforming the S&P 500 by 4.16 points, and is currently trading ~9% below its 52-week high of $426.98. This suggests near-term momentum has stalled within the larger recovery trend.
- High Short Interest as a Contrarian Signal: A short ratio of 4.03 indicates elevated short interest. This suggests a segment of the market is betting against the stock, likely due to concerns over margin pressure, regulatory risks, or valuation.
ELV Technical Analysis
The stock is in a sustained recovery trend from a significant drawdown, evidenced by a 33.29% gain over the past three months, which starkly contrasts with its modest 3.35% one-year price change. As of the latest close of $388.50, the stock is trading at approximately 74% of its 52-week range ($273.71 to $426.98), positioning it in the upper-mid portion of the range, suggesting regained momentum but not yet at overextended highs. Recent short-term momentum is mixed, with a 3.42% decline over the past month indicating a pullback within the larger recovery, yet the stock has demonstrated strong relative strength versus the market, outperforming the S&P 500 by 18.15 percentage points over three months despite the recent monthly underperformance of 4.16 points. Key technical levels are clearly defined by the 52-week high of $426.98 as immediate resistance and the 52-week low of $273.71 as major support; a decisive breakout above resistance would confirm the recovery trend's strength, while a breakdown below support would signal a failure of the recent rally. The stock's beta of 0.68 indicates it is approximately 32% less volatile than the broader market, which is a critical factor for risk management as it suggests the stock may offer defensive characteristics during market downturns but may also lag in strong bull markets.
Beta
0.68
0.68x market volatility
Max Drawdown
-33.4%
Largest decline past year
52-Week Range
$274-$427
Price range past year
Annual Return
+6.1%
Cumulative gain past year
| Period | ELV Return | S&P 500 |
|---|---|---|
| 1m | +0.1% | -1.6% |
| 3m | +33.4% | +11.7% |
| 6m | +15.1% | +6.3% |
| 1y | +6.1% | +22.2% |
| ytd | +11.5% | +7.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ELV Fundamental Analysis
Revenue growth remains robust but showed deceleration in the most recent quarter; Q4 2025 revenue of $49.75 billion grew 9.47% year-over-year, a solid pace, though it decelerated from the 12.4% YoY growth seen in Q3 2025. Segment data reveals the Health Benefits segment, at $41.84 billion, is the primary revenue driver, while the Carelon Services segment contributed $18.66 billion, indicating a diversified business model beyond pure insurance. The company is profitable with a net income of $547 million in Q4 2025, but profitability metrics show significant quarterly volatility, as the net margin compressed to 1.10% in Q4 from 2.34% in Q3 and 4.47% in Q1 2025, while the gross margin also contracted sequentially to 23.48% from 24.79% in the prior quarter. The balance sheet and cash flow position is strong, with a manageable debt-to-equity ratio of 0.76, a healthy current ratio of 1.24, and robust annual free cash flow generation of $3.17 billion on a trailing twelve-month basis, providing ample internal funding for growth and shareholder returns. Return on equity of 12.90% indicates efficient use of shareholder capital, and the company's financial health is further supported by its substantial scale, with a market capitalization of approximately $77.75 billion.
Quarterly Revenue
$49.7B
2025-12
Revenue YoY Growth
+0.09%
YoY Comparison
Gross Margin
+0.23%
Latest Quarter
Free Cash Flow
$3.2B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ELV Overvalued?
Given the company's consistent profitability with positive net income, the primary valuation metric selected is the Price-to-Earnings (PE) ratio. The stock trades at a trailing PE of 13.73x and a forward PE of 13.28x, with the minimal gap between the two suggesting the market expects relatively stable earnings growth in the near term. Compared to typical healthcare plan peers, a trailing PE in the low-to-mid teens often represents a discount, though a direct industry average from the provided data is not available for precise quantification; the valuation appears reasonable relative to the company's growth profile and defensive characteristics. Historically, the current trailing PE of 13.73x sits near the lower end of its own historical range observed over recent quarters, which has spanned from approximately 11.28x to over 35x, suggesting the stock may be trading at a value-oriented multiple relative to its own history, potentially pricing in concerns over margin volatility or regulatory risks rather than optimistic growth expectations.
PE
13.9x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 11x~50x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
10.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: The primary risk is severe earnings volatility, as evidenced by the net margin collapsing from 4.47% in Q1 2025 to 1.10% in Q4 2025. This unpredictability makes forecasting difficult and could trigger multiple compression if it persists. While the balance sheet is strong (D/E 0.76), the company's revenue growth decelerated to 9.47% YoY in Q4 from 12.4% in Q3, indicating potential top-line headwinds. Furthermore, dependence on government-sponsored programs (Medicare/Medicaid) creates concentration risk, where changes in reimbursement rates directly impact profitability.
Market & Competitive Risks: Despite its low beta (0.68) offering defensive appeal, ELV trades at a valuation (13.7x PE) that may already reflect its stable, low-growth profile, leaving limited room for multiple expansion. The stock recently experienced a max drawdown of -33.41%, demonstrating its vulnerability to sector-wide sell-offs, often triggered by regulatory fears. Competitive intensity in the managed care and PBM spaces could pressure pricing and margins, while the high short ratio (4.03) indicates a skeptical investor cohort ready to amplify any negative news.
Worst-Case Scenario: The worst-case scenario involves a combination of sustained margin erosion, a reversal of the favorable Medicare regulatory environment, and a broader market downturn. This could see the stock re-test its 52-week low of $273.71, representing a downside of approximately -29.5% from the current price of $388.50. A more realistic severe bear case, aligned with the low analyst target implied by EPS estimates (~$598), still suggests significant risk if earnings disappoint. The chain of events would be: Q3 2026 earnings miss on continued margin pressure, leading to analyst downgrades, followed by sector rotation out of healthcare plans if macro conditions worsen.
FAQ
The key risks are, in order of severity: 1) Financial: Extreme quarterly earnings volatility (Q4 net margin of 1.10% vs. 4.47% in Q1 2025) makes the stock unpredictable. 2) Regulatory: Despite a recent positive update, government reimbursement rates for Medicare/Medicaid are subject to political and budgetary pressures. 3) Competitive: Intense competition in insurance and PBM services could pressure pricing and margins. 4) Market: The stock has a high short ratio (4.03) and recently suffered a -33.41% max drawdown, indicating vulnerability to sentiment shifts and sector sell-offs.
The 12-month forecast presents three scenarios. The Base Case (50% probability) sees the stock trading between $580-$620, assuming moderate margin improvement and stable high-single-digit revenue growth. The Bull Case (30% probability) targets $598-$646, driven by margin recovery and full benefit from the CMS payment boost. The Bear Case (20% probability) risks a decline to the $274-$350 range if margin weakness persists. The most likely outcome is the Base Case, as it balances the positive regulatory catalyst with the acknowledged challenge of stabilizing quarterly profitability.
ELV appears fairly valued to slightly undervalued relative to its own history. Its trailing PE of 13.73x sits near the lower end of its historical range (from ~11x to over 35x). For a large, profitable insurer with a 12.9% ROE and defensive characteristics, this multiple is reasonable. The market is pricing in concerns over margin volatility and regulatory risk rather than optimistic growth. Compared to typical healthcare plan peers, a low-to-mid teens PE often represents a discount, suggesting ELV is not overvalued and may offer value if earnings stabilize.
ELV is a conditional buy for value-oriented, patient investors. The stock trades at an attractive 13.7x PE with a ~59% upside to analyst targets and benefits from a positive Medicare regulatory catalyst. However, it carries significant risk due to severe quarterly earnings volatility, as seen in the net margin drop to 1.10% in Q4 2025. It is a good buy for those who believe profitability will stabilize, but investors seeking consistent earnings or low risk should wait for clearer evidence from upcoming quarterly reports.
ELV is more suitable for a long-term investment horizon of 2-3 years minimum. Its low beta (0.68) and dividend (1.97% yield) support a buy-and-hold approach, while the resolution of margin issues and realization of regulatory tailwinds will take multiple quarters. The stock's recent volatility and earnings uncertainty make it a poor candidate for short-term trading. A long-term horizon allows investors to capture the potential valuation re-rating as earnings visibility improves and to weather the inevitable quarterly volatility inherent in the managed care sector.